Biotech Growth Valuation
| BIOG Stock | 778.00 8.00 1.02% |
At this time, the firm appears to be overvalued. Biotech Growth shows a prevailing Real Value of USD638.92 per share. The current price of the firm is USD778.0. Our model approximates the value of Biotech Growth from analyzing the firm fundamentals such as Return On Equity of 0.3, operating margin of 0.80 %, and Profit Margin of 0.95 % as well as examining its technical indicators and probability of bankruptcy.
Price Book 0.8949 | Enterprise Value 260.1 M | Price Sales 4.898 | Enterprise Value Revenue 4.962 |
Overvalued
Today
Please note that Biotech Growth's price fluctuation is very steady at this time. Calculation of the real value of Biotech Growth is based on 3 months time horizon. Increasing Biotech Growth's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Biotech stock is determined by what a typical buyer is willing to pay for full or partial control of The Biotech Growth. Since Biotech Growth is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biotech Stock. However, Biotech Growth's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 778.0 | Real 638.92 | Hype 788.5 | Naive 848.36 |
The intrinsic value of Biotech Growth's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Biotech Growth's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of The Biotech Growth helps investors to forecast how Biotech stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biotech Growth more accurately as focusing exclusively on Biotech Growth's fundamentals will not take into account other important factors: Biotech Growth Cash |
|
Biotech Growth Total Value Analysis
The Biotech Growth is currently projected to have takeover price of 260.08 M with market capitalization of 205.77 M, debt of 5.42 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Biotech Growth fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
260.08 M | 205.77 M | 5.42 M |
Biotech Growth Investor Information
About 36.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.89. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biotech Growth last dividend was issued on the 4th of July 2001. The Biotech Growth is not in a good financial situation at this time. It has a very high probability of going through financial hardship in August.Biotech Growth Asset Utilization
One of the ways to look at asset utilization of Biotech is to check how much profit was generated for every dollar of assets it reports. The Biotech Growth utilizes its assets approximately 0.1698 percent, earning 0.17 cents for each dollar of assets held by the firm. An expanding asset utilization signifies that the company is being more effective with each dollar of assets it shows. Put another way, asset utilization of Biotech Growth shows how effective it operates for each dollar spent on its assets.Biotech Growth Ownership Allocation
Biotech Growth holds a total of 26.37 Million outstanding shares. 30% of The Biotech Growth outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Biotech Growth Profitability Analysis
Net Loss for the year was (82.52 M) with profit before overhead, payroll, taxes, and interest of 101.17 M.About Biotech Growth Valuation
The stock valuation mechanism determines Biotech Growth's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Biotech Growth based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Biotech Growth. We calculate exposure to Biotech Growth's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biotech Growth's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -78.8 M | -74.9 M |
Additional Tools for Biotech Stock Analysis
When running Biotech Growth's price analysis, check to measure Biotech Growth's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotech Growth is operating at the current time. Most of Biotech Growth's value examination focuses on studying past and present price action to predict the probability of Biotech Growth's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotech Growth's price. Additionally, you may evaluate how the addition of Biotech Growth to your portfolios can decrease your overall portfolio volatility.